MEDICLIN AG (MED.DE) Stock Fundamental Analysis
FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR
MED gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 25 industry peers in the Health Care Providers & Services industry. While MED is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
In the past year MED had a positive cash flow from operations.
In multiple years MED reported negative net income over the last 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED has a better Return On Assets (2.91%) than 64.00% of its industry peers.
MED has a better Return On Equity (11.67%) than 72.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.78%, MED is in the better half of the industry, outperforming 64.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 5.74%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(5.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.91% | ||
| ROE | 11.67% | ||
| ROIC | 5.78% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
The Profit Margin of MED (3.41%) is better than 72.00% of its industry peers.
In the last couple of years the Profit Margin of MED has grown nicely.
Looking at the Operating Margin, with a value of 7.13%, MED is in line with its industry, outperforming 56.00% of the companies in the same industry.
MED's Operating Margin has improved in the last couple of years.
The Gross Margin of MED (83.54%) is better than 80.00% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.13% | ||
| PM (TTM) | 3.41% | ||
| GM | 83.54% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MED has about the same amount of shares outstanding.
The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
MED has a better debt/assets ratio than last year.
2.2 Solvency
MED has an Altman-Z score of 1.64. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.64, MED perfoms like the industry average, outperforming 48.00% of the companies in the same industry.
The Debt to FCF ratio of MED is 13.36, which is on the high side as it means it would take MED, 13.36 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MED (13.36) is worse than 64.00% of its industry peers.
A Debt/Equity ratio of 1.92 is on the high side and indicates that MED has dependencies on debt financing.
The Debt to Equity ratio of MED (1.92) is worse than 72.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | 13.36 | ||
| Altman-Z | 1.64 |
ROIC/WACC1.24
WACC4.67%
2.3 Liquidity
A Current Ratio of 1.81 indicates that MED should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.81, MED is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
MED has a Quick Ratio of 1.76. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.76, MED belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 541.24%, which is quite impressive.
MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
The Revenue has decreased by -1.47% in the past year.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)541.24%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%88.47%
Revenue 1Y (TTM)-1.47%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%0.33%
3.2 Future
MED is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.48% yearly.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.53, which indicates a rather cheap valuation of MED.
Based on the Price/Earnings ratio, MED is valued cheaper than 96.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of MED to the average of the S&P500 Index (26.54), we can say MED is valued rather cheaply.
The Price/Forward Earnings ratio is 5.79, which indicates a rather cheap valuation of MED.
Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 96.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.28, MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.53 | ||
| Fwd PE | 5.79 |
4.2 Price Multiples
92.00% of the companies in the same industry are more expensive than MED, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MED is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.22 | ||
| EV/EBITDA | 3.36 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
PEG (NY)0.27
PEG (5Y)0.27
EPS Next 2Y12.62%
EPS Next 3Y6.48%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.27%.
MED's Dividend Yield is comparable with the industry average which is at 2.85.
Compared to an average S&P500 Dividend Yield of 2.40, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.27% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
FRA:MED (8/7/2025, 7:00:00 PM)
3.04
+0.02 (+0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.7%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap144.40M
Analysts83.33
Price Target4.79 (57.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.27% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.53 | ||
| Fwd PE | 5.79 | ||
| P/S | 0.19 | ||
| P/FCF | 4.22 | ||
| P/OCF | 1.79 | ||
| P/B | 0.65 | ||
| P/tB | 0.73 | ||
| EV/EBITDA | 3.36 |
EPS(TTM)0.55
EY18.09%
EPS(NY)0.53
Fwd EY17.28%
FCF(TTM)0.72
FCFY23.68%
OCF(TTM)1.69
OCFY55.76%
SpS16.12
BVpS4.71
TBVpS4.19
PEG (NY)0.27
PEG (5Y)0.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.91% | ||
| ROE | 11.67% | ||
| ROCE | 7.45% | ||
| ROIC | 5.78% | ||
| ROICexc | 7.6% | ||
| ROICexgc | 7.95% | ||
| OM | 7.13% | ||
| PM (TTM) | 3.41% | ||
| GM | 83.54% | ||
| FCFM | 4.47% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score6
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | 13.36 | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 90.73% | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | 2.42 | ||
| Cash Conversion | 76.2% | ||
| Profit Quality | 131.16% | ||
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | 1.64 |
F-Score6
WACC4.67%
ROIC/WACC1.24
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)541.24%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%88.47%
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.47%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%0.33%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y195.75%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y276.49%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y107.99%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%